Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
ribavarin elaidate (TRX-201) (formerly CP-4033)
print preview
bookmark
share with colleague
General Information
Company
Clavis Pharma ASA
Description
Lipid Vector Technology (LVT) derivative of ribavirin which inhibits eukaryotic translation initiation factor 4E (eIF4E)
Molecular Target
Eukaryotic translation initiation factor 4E (eIF4E)
Mechanism of Action
Latest Stage of Development
Preclinical
Indication
Thyroid cancer
Partner
Translational Therapeutics Inc.
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Archive Items are loading
Set Email Alert
dummy